Natalizumab (Tysabri)

Tysabri (natalizumab) is covered for FDA‑approved uses — relapsing forms of multiple sclerosis and moderately‑to‑severely active Crohn’s disease — only for adults (≥18) and limited to 300 mg IV no more frequently than every 4 weeks. Coverage requires specialist prescribing/consultation (MS specialist/neurologist or gastroenterologist), MS patients must have failed ≥1 disease‑modifying therapy or have highly‑active disease, Crohn’s patients must have tried ≥2 biologics, documentation for initial and reauthorization (including demonstrated response for Crohn’s and ongoing relapsing disease for MS) is required, and approval durations are MS: 1 year; Crohn’s: initial 3 months, reauth 1 year.

"FDA-approved indication: Multiple Sclerosis"

Sign up to see full coverage criteria, indications, and limitations.